{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:10:31Z","timestamp":1792426231564,"version":"4.5.0"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303764"],"award-info":[{"award-number":["82303764"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chimeric antigen receptor T cell therapy has limited efficacy in the treatment of glioma due to the blood-brain barrier and T cell exhaustion. Enhancement with rabies virus glycoprotein (RVG29) has shown improved brain-related efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this study, we developed CD70R CAR-T cells by modifying anti-CD70 CAR-T cells with RVG29 and tested their tumor-killing ability\n                      <jats:italic>in vitro<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Transcriptomic profiling via RNA-seq revealed the activated signaling pathways in modified CD70R CAR-T cells. These cells displayed effective\n                      <jats:italic>in vitro<\/jats:italic>\n                      cytotoxicity against CD70\n                      <jats:sup>+<\/jats:sup>\n                      ; glioma cells, furthermore, co-culture with glioma cells promoted the expansion of quiescent CD70R CAR-T cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The RVG29 modification enhances CAR-T therapy for brain tumors and holds promise for treating glioma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1680513","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T13:26:51Z","timestamp":1775482011000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Genomic characterization of rabies virus glycoprotein co-expressing CD70 CAR-T cells during killing of glioma cells in vitro"],"prefix":"10.3389","volume":"17","author":[{"given":"Feng","family":"Ji","sequence":"first","affiliation":[{"name":"Office of Research Platform Management, Zhongda Hospital, School of Medicine, Southeast University","place":["Nanjing, China"]},{"name":"National Medical Research of Industry-Education Integration Innovation Platform for Interventional Medica Engineering, Zhongda Hospital, Southeast University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexing","family":"Gao","sequence":"additional","affiliation":[{"name":"Office of Research Platform Management, Zhongda Hospital, School of Medicine, Southeast University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianchen","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Shuyang Zhongxing Hospital","place":["Suqian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Lin","sequence":"additional","affiliation":[{"name":"Office of Research Platform Management, Zhongda Hospital, School of Medicine, Southeast University","place":["Nanjing, China"]},{"name":"National Medical Research of Industry-Education Integration Innovation Platform for Interventional Medica Engineering, Zhongda Hospital, Southeast University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.3390\/cancers15082351","article-title":"Gene targets of CAR-T cell therapy for glioblastoma","volume":"15","author":"Wang","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2020.02.002","article-title":"Immunotherapy for glioma: Current management and future application","volume":"476","author":"Xu","year":"2020","journal-title":"Cancer Lett"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.7150\/thno.53506","article-title":"Beyond glucose: alternative sources of energy in glioblastoma","volume":"11","author":"Caniglia","year":"2021","journal-title":"Theranostics"},{"key":"B4","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/s41419-025-07969-3","article-title":"USP7 promotes temozolomide resistance by stabilizing MGMT in glioblastoma","volume":"16","author":"Li","year":"2025","journal-title":"Cell Death Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41551-020-00621-9","article-title":"A microfluidic cell-migration assay for the prediction of progression-free survival and recurrence time of patients with glioblastoma","volume":"5","author":"Wong","year":"2021","journal-title":"Nat BioMed Eng"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-025-03663-y","article-title":"Dual-target CAR-T therapy for ovarian cancer: synergistic targeting of MSLN and B7H3 enhances anti-tumor efficacy and overcomes antigen heterogeneity","volume":"45","author":"Ji","year":"2026","journal-title":"Oncogene"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nox182","article-title":"Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma","volume":"20","author":"Bielamowicz","year":"2018","journal-title":"Neuro Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.1172\/JCI131246","article-title":"Tandem CAR T cells targeting HER2 and IL13Ralpha2 mitigate tumor antigen escape","volume":"129","author":"Hegde","year":"2019","journal-title":"J Clin Invest"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw2672","article-title":"Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma","volume":"12","author":"Wang","year":"2020","journal-title":"Sci Transl Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","article-title":"CAR-T cell therapy for cancer: current challenges and future directions","volume":"10","author":"Zugasti","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B11","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-024-01625-7","article-title":"Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies","volume":"17","author":"Ai","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0827-2","article-title":"Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma","volume":"26","author":"Donovan","year":"2020","journal-title":"Nat Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab022","article-title":"Blood-brain barrier alterations in human brain tumors revealed by genome-wide transcriptomic profiling","volume":"23","author":"Schaffenrath","year":"2021","journal-title":"Neuro Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-11-0284","article-title":"Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors","volume":"2","author":"Vivanco","year":"2012","journal-title":"Cancer Discov"},{"key":"B15","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2174\/1389203033487289","article-title":"Modulation of cellular function by TAT mediated transduction of full-length proteins","volume":"4","author":"Wadia","year":"2003","journal-title":"Curr Protein Pept Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2174\/1568026616666161222101355","article-title":"Nanocarriers for effective brain drug delivery","volume":"17","author":"Comoglu","year":"2017","journal-title":"Curr Top Med Chem"},{"key":"B17","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ejps.2010.05.003","article-title":"Strategy for effective brain drug delivery","volume":"40","author":"Alam","year":"2010","journal-title":"Eur J Pharm Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2012.09.047","article-title":"Brain-targeted delivery of protein using chitosan- and RVG peptide-conjugated, pluronic-based nano-carrier","volume":"34","author":"Kim","year":"2013","journal-title":"Biomaterials"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nox175","article-title":"Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data","volume":"20","author":"Sarkaria","year":"2018","journal-title":"Neuro Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e62905","DOI":"10.1371\/journal.pone.0062905","article-title":"Targeting caspase-3 as dual therapeutic benefits by RNAi facilitating brain-targeted nanoparticles in a rat model of Parkinson\u2019s disease","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS One"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2009.02.051","article-title":"Brain-targeting gene delivery and cellular internalization mechanisms for modified rabies virus glycoprotein RVG29 nanoparticles","volume":"30","author":"Liu","year":"2009","journal-title":"Biomaterials"},{"key":"B22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40035-025-00484-7","article-title":"Development of human targeted extracellular vesicles loaded with shRNA minicircles to prevent parkinsonian pathology","volume":"14","author":"Izco","year":"2025","journal-title":"Transl Neurodegener"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e70031","DOI":"10.1002\/jev2.70031","article-title":"A simple polydopamine-based platform for engineering extracellular vesicles with brain-targeting peptide and imaging probes to improve stroke outcome","volume":"14","author":"Shi","year":"2025","journal-title":"J Extracell Vesicles"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.trsl.2023.03.003","article-title":"Rabies virus glycoprotein 29 (RVG29) promotes CAR-T immunotherapy for glioma","volume":"259","author":"Ji","year":"2023","journal-title":"Transl Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01168-1","article-title":"Targeting the DNA damage response enhances CD70 CAR-T cell therapy for renal carcinoma by activating the cGAS-STING pathway","volume":"14","author":"Ji","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e3465","DOI":"10.21769\/BioProtoc.3465","article-title":"Semi-quantitative determination of protein expression using immunohistochemistry staining and analysis: an integrated protocol","volume":"9","author":"Crowe","year":"2019","journal-title":"Bio Protoc"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz1863","article-title":"Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors","volume":"12","author":"Park","year":"2020","journal-title":"Sci Transl Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2019.119666","article-title":"An iRGD-conjugated prodrug micelle with blood-brain-barrier penetrability for anti-glioma therapy","volume":"230","author":"Lu","year":"2020","journal-title":"Biomaterials"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-014-8516-1","article-title":"ImmPort: disseminating data to the public for the future of immunology","volume":"58","author":"Bhattacharya","year":"2014","journal-title":"Immunol Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2024.167649","article-title":"Investigating the landscape of immune-related genes and immunophenotypes in atherosclerosis: A bioinformatics Mendelian randomization study","volume":"1871","author":"Zhang","year":"2024","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"B31","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/s13046-018-1002-1","article-title":"Classification of triple-negative breast cancers based on Immunogenomic profiling","volume":"37","author":"He","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2023.10.004","article-title":"Engineered extracellular vesicles efficiently deliver CRISPR-Cas9 ribonucleoprotein (RNP) to inhibit herpes simplex virus1 infection in vitro and in vivo","volume":"14","author":"Wan","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.2c12840","article-title":"Multiscale NIR-II imaging-guided brain-targeted drug delivery using engineered cell membrane nanoformulation for alzheimer\u2019s disease therapy","volume":"17","author":"Huang","year":"2023","journal-title":"ACS Nano"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2023.04.001","article-title":"Extracellular vesicle-based delivery of silencing sequences for the treatment of MaChado-Joseph disease\/spinocerebellar ataxia type 3","volume":"31","author":"Rufino-Ramos","year":"2023","journal-title":"Mol Ther"},{"key":"B35","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/neuonc\/nox116","article-title":"CD70, a novel target of CAR T-cell therapy for gliomas","volume":"20","author":"Jin","year":"2018","journal-title":"Neuro Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","article-title":"Structure and function of the blood-brain barrier","volume":"37","author":"Abbott","year":"2010","journal-title":"Neurobiol Dis"},{"key":"B37","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/cns.13569","article-title":"Peripheral inflammation and blood-brain barrier disruption: effects and mechanisms","volume":"27","author":"Huang","year":"2021","journal-title":"CNS Neurosci Ther"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00139-y","article-title":"Strategies for delivering therapeutics across the blood-brain barrier","volume":"20","author":"Terstappen","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.2013.160","article-title":"Brain bioavailability of human intravenous immunoglobulin and its transport through the murine blood-brain barrier","volume":"33","author":"St-Amour","year":"2013","journal-title":"J Cereb Blood Flow Metab"},{"key":"B40","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s11095-020-02865-1","article-title":"RVG29-functionalized lipid nanoparticles for quercetin brain delivery and alzheimer\u2019s disease","volume":"37","author":"Pinheiro","year":"2020","journal-title":"Pharm Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12020093","article-title":"Targeting small molecule delivery to the brain and spinal cord via intranasal administration of rabies virus glycoprotein (RVG29)-modified PLGA nanoparticles","volume":"12","author":"Chung","year":"2020","journal-title":"Pharmaceutics"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e2201322","DOI":"10.1002\/adma.202201322","article-title":"Engineered nanoerythrocytes alleviate central nervous system inflammation by regulating the polarization of inflammatory microglia","volume":"34","author":"Yin","year":"2022","journal-title":"Adv Mater"},{"key":"B43","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12967-023-04044-3","article-title":"CCL5\/CCR5-mediated peripheral inflammation exacerbates blood\u2013brain barrier disruption after intracerebral hemorrhage in mice","volume":"21","author":"Lin","year":"2023","journal-title":"J Transl Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"6666","DOI":"10.1038\/s41467-021-27056-3","article-title":"GAPDH controls extracellular vesicle biogenesis and enhances the therapeutic potential of EV mediated siRNA delivery to the brain","volume":"12","author":"Dar","year":"2021","journal-title":"Nat Commun"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat0195","article-title":"Anchor peptide captures, targets, and loads exosomes of diverse origins for diagnostics and therapy","volume":"10","author":"Gao","year":"2018","journal-title":"Sci Transl Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2020.146738","article-title":"Efficient neuronal targeting and transfection using RVG and transferrin-conjugated liposomes","volume":"1734","author":"Dos","year":"2020","journal-title":"Brain Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41578-021-00394-w","article-title":"Drug delivery to the central nervous system","volume":"7","author":"Nance","year":"2022","journal-title":"Nat Rev Mater"},{"key":"B48","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Mol Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02893-z","article-title":"Intrathecal\u00a0bivalent CAR T cells targeting EGFR and IL13Ralpha2 in recurrent glioblastoma: phase 1 trial interim results","volume":"30","author":"Bagley","year":"2024","journal-title":"Nat Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003289","article-title":"CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment","volume":"10","author":"Seyfrid","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41435-024-00275-6","article-title":"HER2-targeting CAR-T cells show highly efficient anti-tumor activity against glioblastoma both in vitro and in vivo","volume":"25","author":"Li","year":"2024","journal-title":"Genes Immun"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2401307","article-title":"CAR T-cell therapy for glioblastoma","volume":"390","author":"Jenkins","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1680513\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T13:26:52Z","timestamp":1775482012000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1680513\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":53,"alternative-id":["10.3389\/fimmu.2026.1680513"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1680513","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,6]]},"article-number":"1680513"}}